Australian drugmaker Dia-B has finished Phase I trials of ISF402, its Type 2 diabetes drug, and will start planning for Phase II studies.

The single-center, double-blind pharmacokinetic study enrolled 32 healthy male volunteers and 11 patients with Type 2 diabetes. There were no adverse events associated with the drug, which demonstrated oral availability.

Michael Wooldridge, Dia-B’s chairman, said the company expects to begin Phase II trials in late 2008.